Madrigal Pharmaceuticals, Inc.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. carries a market capitalization of 10.87B, placing it among publicly traded companies globally. Its enterprise value stands at 10.44B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Madrigal Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. has 23.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 10.84, and the price-to-book ratio stands at 23.71.

These figures are as of June 30, 2026. The EV/Sales ratio of 9.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.44B versus a market cap of 10.87B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. maintains a current ratio of 3.20, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 66.40, indicating elevated leverage, while an interest coverage ratio of -10.19 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Madrigal Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -53.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.77, reflecting losses generated across the asset base. The company generates approximately 1.37M in revenue per employee across its workforce of 818.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.34 indicates how many times Madrigal Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Madrigal Pharmaceuticals, Inc.'s stock has gained approximately 12.74% over the past 52 weeks. The 50-day moving average sits at 445.56, while the 200-day moving average is 434.17.

Over the twelve months ended June 30, 2026, Madrigal Pharmaceuticals, Inc. generated 1.12B in revenue and converted that into -284.56M in net income, yielding earnings per share of -11.00. EBITDA reached -281.06M, while operating income came in at -282.38M.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. holds 734.16M in cash and equivalents against 304.39M in total debt, resulting in a net debt position of 42.07M. Total book value stands at 458.42M, with working capital of 722.10M providing operational flexibility.

Madrigal Pharmaceuticals, Inc. produced -173.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -10.13M in capital expenditures, free cash flow totaled -183.19M - equivalent to -7.08 per share.

Over the twelve months ended June 30, 2026, Madrigal Pharmaceuticals, Inc. posted a gross margin of 91.48, reflecting its pricing power and cost economics. The operating margin of -25.13 and net profit margin of -25.32 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -1.50: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -2.02, meaning Madrigal Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Madrigal Pharmaceuticals, Inc.'s most recent stock split took place on July 26, 2016 with a 35:1 split ratio.

As of June 30, 2026, Madrigal Pharmaceuticals, Inc. has an Altman Z-Score of 8.78, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.